Previous
Previous

Dr. Rippee speaks about enrolling patients in Oxeia’s Phase 2 Clinical Trial for Concussions on KU’s Morning Medical Update

Next
Next

News Release: OXEIA BIOPHARMACEUTICALS ANNOUNCES NEW BOARD AND MANAGEMENT TEAM MEMBERS AND RELOCATES CORPORATE HEADQUARTERS TO BOSTON